What we do Venmax Drugs & Pharmaceuticals Ltd develops and markets pharmaceutical products, drug intermediaries, and APIs, focusing on oncology R&D and establishing a retail pharma chain. |
Founded in 1,998 |
Market share Emerging player in pharmaceutical manufacturing and retail pharmacy sectors in India. |
Problem solved Provides essential pharmaceuticals and oncology products, improving healthcare access via own retail chain. |
Top clients or who we serve B2B pharmaceutical clients, healthcare providers, and B2C through 'Ananya Pharma' retail stores. |
Key management - |
Our journey and innovations Evolved since 1998, transitioned to public in 1995, rebranded in 2009; expanding with cGMP plant and oncology R&D. |
Where we operate India, with expansion plans for exports and domestic pharma cluster manufacturing at Hyderabad. |
Top products or what we offer Pharmaceutical formulations, drug intermediates, Active Pharmaceutical Ingredients (APIs), oncology products under development, and retail pharmacy services. |
Top brands Ananya Pharma (retail chain); Suzichem Labs (formulations manufacturing). |
Raw materials needed Chemical intermediates and raw materials for pharmaceutical synthesis and formulations. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue currently cyclical with expected increase in recurring income from retail pharmacy operations. |
Our industry position Small but growing firm with expansion plans into oncology and retail pharma sectors. |
Financial highlights FY 2024-25 revenue Rs. 80.73 Lakhs; net loss Rs. 1.05 Lakhs; recently increased authorized share capital. |
Geographical revenue split - |
Order book - |
Whats driving growth Expansion into medical retail stores, new cGMP manufacturing unit, and oncology R&D drive growth. |
Our future plans Establish cGMP manufacturing facility in Hyderabad; expand Ananya Pharma retail chain; grow oncology product portfolio. |
Our green promise - |
Our people and values Committed to employee welfare and corporate governance with regular board evaluations and compliance. |
Key challenges ahead Recovering profitability, market competition, successful scale-up of manufacturing and retail operations. |
Interesting facts Company evolved through multiple name changes since 1998; focusing on oncology-specific pharmaceutical innovation. |
Risks and strategy Managing business risks via strong governance; focusing on new product development and diversified revenue streams. |
